Newron Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan '26 Jan 29, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	426	186	95	28	28	35
Market Cap Growth	125.27%	95.60%	239.07%	0.38%	-21.34%	-66.00%
Enterprise Value	435	223	126	44	33	22
Last Close Price	21.80	9.29	5.60	1.47	1.50	1.91
PE Ratio	16.81	11.72	-	-	-	-
PS Ratio	7.11	3.61	10.48	4.59	4.84	6.74
PB Ratio	269.06	127.32	-3.17	-1.99	8.98	2.06
P/TBV Ratio	269.23	127.32	-	-	8.98	2.06
EV/Sales Ratio	7.13	4.34	13.95	7.26	5.77	4.13
EV/EBITDA Ratio	12.06	8.52	-	-	-	-
EV/EBIT Ratio	12.13	8.53	-	-	-	-
Debt / Equity Ratio	33.23	34.62	-1.62	-3.25	13.87	1.53
Debt / EBITDA Ratio	1.49	1.91	-	-	-	-
Asset Turnover	1.39	1.15	0.29	0.14	0.11	0.09
Quick Ratio	1.40	2.42	0.62	5.50	10.58	5.50
Current Ratio	1.51	2.60	0.68	5.65	10.79	5.50
Return on Equity (ROE)	-	-	-	-	-146.43%	-77.71%
Return on Assets (ROA)	50.97%	36.44%	-23.05%	-18.96%	-15.19%	-20.26%
Return on Invested Capital (ROIC)	263.58%	80.74%	-157.51%	-130.08%	-103.26%	-134.50%
Return on Capital Employed (ROCE)	165.20%	64.80%	380.00%	-41.40%	-26.40%	-40.80%
Earnings Yield	5.95%	8.54%	-17.09%	-62.50%	-53.44%	-59.23%
FCF Yield	5.76%	-9.50%	-10.70%	-39.69%	-41.12%	-44.07%
Buyback Yield / Dilution	-16.86%	-15.30%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.